Financial News · Live Terminal

Page 385 of 857

TransThera Sciences Completes HK$157 Million Share Offering

TransThera Sciences (Nanjing) (HKG:2617) said it completed a HK$156.6 million share offering, according to a Wednesday filing with the Hong Kong bourse.The drugmaker's shares fell over 5% in late morning trade Thursday.The company sold 3.8 million shares priced at HK$40.83 each to raise funds for the development of new indications for its core product, tinengotinib.The shares represent 1.23% of the company's existing H shares and 0.94% of its enlarged share capital.

HKG:2617

Asia44d ago

GR Life Style Board Proposes Name Change

GR Life Style (HKG:0108) said its board proposed changing the company's name to SR Medical Technology, according to a Wednesday filing with the Hong Kong bourse.The real estate company's shares gained nearly 3% in late morning trade Thursday.The company said it will seek shareholder approval on the proposal to provide a new corporate identity and image.

HKG:0108

Asia44d ago

Damai Entertainment's Fiscal Profit Jumps 94%

Damai Entertainment (HKG:1060) recorded 705.2 million yuan in attributable profit for the fiscal year ended March 31, up 94% from 363.6 million yuan a year earlier, according to a Wednesday filing with the Hong Kong bourse.The motion picture company's shares fell over 6% in late morning trade Thursday.Earnings per share were 0.0235 yuan, compared with 0.0123 yuan in the prior fiscal year.Revenue rose 20% year on year to 8.02 billion yuan, figures showed.

HKG:1060

Asia44d ago

Sihuan Pharmaceutical Trustee Buys Back 8 Million Shares Under Incentive Plan; Stock Slides 4%

Sihuan Pharmaceutical's (HKG:0460) trustee bought back 8 million shares of the firm from the market for around HK$1.0052 apiece under a 2022 share award scheme, according to a Wednesday filing with the Hong Kong bourse.The company's shares fell nearly 4% in late morning trade Thursday.The shares represent 0.0877% of the pharma firm's issued share capital.

HKG:0460

Asia44d ago

Consun Pharma Launches HK$200 Million Share Buyback Program; Shares Slip 3%

Consun Pharmaceutical (HKG:1681) launched a share repurchase program of up to HK$200 million under its general buyback mandate, according to a Wednesday Hong Kong bourse filing.Shares of the firm were down nearly 3% in Thursday's midday trade.The company said the program will run from May 27 through Dec. 31, with shares to be repurchased on the open market.Consun intends to fund the repurchases using available cash.

HKG:1681

Asia44d ago

Peet Makes 'Meaningful Positive Upgrade' to Fiscal 2026 Profit Outlook, Euroz Hartleys Says; Shares Rise 9%

Peet's (ASX:PPC) increased earnings guidance "is a meaningful positive upgrade" that reflects a continuation of strong operating performance and sustained demand in important markets, Euroz Hartleys said in a Thursday note.The company raised its fiscal year 2026 net profit after tax guidance to between AU$98 million and AU$100 million from a previous range of AU$86 million to AU$90 million, representing growth of 67% to 71% from fiscal year 2025.The upgrade puts Peet materially ahead of Euroz Hartleys' AU$87.2 million forecast, which the equity research firm is now reviewing.Peet is also targeting further growth in fiscal year 2027 amid a more cautious macro backdrop, including interest rate hikes, inflation, and cost-of-living pressures. Australia's structural housing shortfall has not been resolved yet, and the company "remains well positioned to deliver into tight supply" in regions like Western Australia and Queensland, Euroz Hartleys said.It maintained a buy recommendation on Peet with an under-review target price of AU$2.76 per share.Peet shares advanced 9% in recent Thursday trade.

ASX:PPC

Asia44d ago

Pharmaron Plans 5 Billion Yuan Investments in Drug Manufacturing Projects; Shares Slip 3%

Pharmaron Beijing (HKG:3759, SHE:300759) plans to invest a combined 5 billion yuan in drug manufacturing and CDMO projects in Zhejiang province, China, according to separate Wednesday filings with the Hong Kong bourse.Hong Kong-listed shares of the pharmaceutical company were down nearly 3% in Thursday's midday trade.The company plans to invest about 2 billion yuan in a new drug commercialization and CDMO production facility in Hangzhou's Qiantang district, with operations expected to begin in 2029.Separately, Pharmaron plans to invest about 3 billion yuan in a Shaoxing project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and active pharmaceutical ingredients, including products for obesity, diabetes, and oncology treatments.The Shaoxing project's first phase is expected to begin operations in 2028, while the second phase is scheduled for 2030, subject to construction progress.

HKG:3759SHE:300759

Asia44d ago

Grand Ming Unit Clears Legal Overhang Following Settlement

A winding-up petition filed against a Grand Ming (HKG:1271) unit was withdrawn in Hong Kong on Wednesday following a settlement, the company said in a same-day filing with the city's bourse.The property developer's shares fell by more than 3% in recent trade.The petition was filed by Jardine Engineering Corporation against Grand Tech Construction over unpaid invoices totaling HK$14.7 million under subcontract works.However, both sides reached a settlement agreement in April, and the petitioner filed an application to withdraw the suit.

HKG:1271

Asia44d ago

Ascent Bridge Skyrockets 48% on Deal to Launch Gene Therapy Centers in Singapore, China

Ascent Bridge (SGX:AWG) signed a cooperation framework agreement with Scinosen (Shenzhen) Gene Industry Development to establish a joint venture in Singapore, according to a Thursday bourse filing.The joint venture will focus on building gene therapy treatment centers in Singapore and China, along with the sales and marketing of gene therapy drug Gendicine, a commercially approved recombinant human p53 gene therapy injection used in oncology treatmentsUnder the finalized equity allocation framework, Ascent Bridge will maintain controlling interest with a stake capped at 70.1%, while Scinosen will retain an equity slice of no less than 19.9%.Following its establishment, the joint venture will pay Scinosen 20 million yuan in cash as upfront payment. A secondary tranche of 30 million yuan will be disbursed upon securing final product and facility clearances from relevant state medical authorities.Additionally, the joint venture will pay Scinosen an amount of up to 1 billion yuan as part of sales milestone payments based on the actual net sales of Gendicine.The new venture is part of the company's strategy to expand within the gene therapy and precision medicine sectors.Shares of the company surged nearly 48% in Thursday afternoon trading.

SGX:AWG

Asia44d ago

Market Chatter: China Approves 15 Domestic Innovative Drugs

Domestic biopharmaceutical developers captured nearly 80% of China's recent innovative drug clearances, marking a major milestone as local pipelines outpace imports.Fifteen of the 19 innovative drugs cleared by the National Medical Products Administration as of May 21 came from domestic companies, The South China Morning Post reported Wednesday.The regulator has overhauled its approval process specifically to fast-track home-grown innovative drugs to market, according to the report.Among those approved was BeOne Medicines' (SHA:688235, HKG:6160) sonrotoclax, used for treating adult blood cancers, the SCMP wrote.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Shanghai Composite^SZSEHKG:6160SHA:688235

Asia44d ago

Robosense Technology's Loss Narrows in Q1; Shares Down 4%

Robosense Technology (HKG:2498) posted a net loss attributable to owners of 64.2 million yuan for the first quarter, narrowing from a loss of 99.6 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Shares of the AI-driven robotics company were down over 4% in late morning trade on Thursday.Loss per share came in at 0.14 yuan, compared with 0.22 yuan in the prior-year period.Revenue increased 40% to 458.8 million yuan from 327.8 million yuan a year earlier.

HKG:2498

Asia44d ago

FEG's Rights Offering Undersubscribed

FEG Holdings (HKG:1413) said its previously announced rights offering was under subscribed, according to a Wednesday filing with the Hong Kong bourse.The construction services provider's shares fell nearly 1% in late morning trade Thursday.The company was looking to raise HK$33.5 million via the sale of up to 164 million rights shares priced at HK$0.214 each, but received acceptances for 83.6 million shares or 51% of the total.The firm said it will now offer the remaining 80.4 million rights shares to external investors.The offering was based on 1 rights shares for every 2 shares held in the company.

HKG:1413

Asia44d ago

XtalPi Receives Further $19 Million Under Drug Discovery Agreement With DoveTree

XtalPi Holdings (HKG:2228) said it received a further $19 million payment from DoveTree Medicines under an AI-driven drug discovery services agreement, according to a Wednesday filing with the Hong Kong bourse.The bio-tech platform's shares gained over 3% recent trade.The firm had previously agreed to use its AI and robotics-enabled platform to develop small molecule and antibody drug candidates across multiple therapeutic areas that would then be licensed to DoveTree.XtalPi received an upfront payment of $51 million at the time and is eligible for milestone payments of up to $5.89 billion and potential royalties on future net sales.

HKG:2228

Asia44d ago

REF Completes HK$23 Million Share Placement; Shares Gain 3%

REF (HKG:1631) completed the placement of 51.2 million new shares at HK$0.457 apiece, raising net proceeds of about HK$22.7 million, according to a Wednesday Hong Kong bourse filing.Shares of the financial printing services business were up over 3% in Thursday's late morning trade.The company said the shares were placed with at least six independent investors.REF plans to use the proceeds for leasing and renovating a new office in Central, additional staff costs for expanded operations, software and IT-related expenses, and other operating expenses by December 2027.

HKG:1631

Asia44d ago

Hong Kong Court Adjourns Winding-up Hearing Against China Water Industry to June 8

China Water Industry (HKG:1129) said a Hong Kong court adjourned the hearing of a winding-up petition against the company to June 8, according to a Wednesday bourse filing.Shares of the water supply company were down over 2% in late morning trade on Thursday.The petition relates to a May 2022 loan agreement involving New China Water (Nanjing) Renewable Resources Investment, an indirect non-wholly owned subsidiary of the company, and a guarantee provided by China Water Industry.

HKG:1129

Asia44d ago

Shuangdeng Group Completes H-Share Circulation

Shuangdeng Group (HKG:6960) completed its planned H-share circulation in Hong Kong, according to a filing with the city's bourse Wednesday.The battery maker's shares gained nearly 6% in late-morning trade Thursday.The firm converted and listed about 191.8 million domestic shares, or 46% of its total issued capital, into H shares under the full circulation scheme.

HKG:6960

Asia44d ago

China's Transport Sector Logs 2% Growth in January-April

China recorded 23.21 billion cross-regional passenger trips from January to April, up 2.1% from last year, state media reported Wednesday.Road passenger traffic rose 1.7%, while waterway trips climbed 7.4%.Commercial cargo handling went up 3.6% to 18.2 billion tonnes. Port cargo throughput rose 3.1% to 5.9 billion tonnes, with container throughput rising 7.2% to 120 million twenty-foot equivalent units.Fixed-asset investment in the transport sector exceeded 894.4 billion yuan during the period.

Shanghai Composite^SZSE

Asia44d ago

Emperor Capital's Fiscal H1 Profit Falls

Emperor Capital Group (HKG:0717) booked HK$39 million in attributable profit for the fiscal first half ended March 31, falling from HK$56.1 million a year earlier, according to a Wednesday filing with the Hong Kong bourse.Shares of the financial services provider fell 11% in recent trade.Basic earnings per share were HK$0.0058, compared with HK$0.0083 in the prior-year period.Revenue fell sharply to HK$147.7 million from HK$402.6 million a year ago.

HKG:0717

Asia44d ago

Eagers Automotive Likely to Grow Deliveries in Fiscal H2, Jefferies Says

Eagers Automotive (ASX:APE) is expected to grow deliveries in the second half of fiscal 2026, supported by improved supply via its scaled partnership with Toyota following a constrained first half, according to a Wednesday note by Jefferies.The company's trading update was "positive" about new order write, and turnover was up around 5% on the prior corresponding period, Jefferies said. Orders taken throughout this period exceeded deliveries by more than 29%, with supply restraints impacting and deferring delivery timing.While Eagers was positive about a supply recovery in the second half, Jefferies opted for a cautious approach and cut fiscal 2026 profit before tax estimate by 3% to account for the reduced ability to convert new orders to deliveries/revenue.The investment firm retained its buy rating and AU$30.50 price target for Eagers Automotive.Eagers Automotive's shares tumbled 8% in recent Thursday trade.

ASX:APE

Asia44d ago

Nufarm's Fiscal H1 Results Confirm Cyclical Inflection in Crop Protection, Seeds, Jefferies Says

Nufarm's (ASX:NUF) fiscal first-half results confirmed a cyclical inflection in crop protection and seeds, alongside an improved cashflow outlook that offers a viable route to deleveraging, Jefferies said in a Wednesday note.The company pointed to lean global channel stocks of crop protection products following a period of destocking, and the correction has largely played out with the market stabilized and growers shifting to just-in-time stocking, the investment firm said.Active ingredient prices are recovering but remain low, which should support margins, as should Nufarm's portfolio reset, Jefferies said."Overall, we see the backdrop stable to better after a very tough period for the industry and growers," the equity research firm added.Jefferies lifted its fiscal year 2027 to fiscal year 2028 earnings before interest, taxes, depreciation, and amortization forecasts on Nufarm by 5% to 6%, partly reflecting stronger performance in the crop protection and seeds segments.It upgraded the company's rating to buy from hold, while raising its price target to AU$3.50 per share from AU$2.66.Nufarm shares gained 2% in recent Thursday trade.

ASX:NUF

Showing 7681-7700 of 17121